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Abstract: Discharge prescriptions for heart failure (HF) patients may not adhere to the clinical
practice guidelines. This study aimed to assess the impact of the clinical pharmacist as a member
of a multidisciplinary team on the quality of prescribing to HF patients at discharge from a Critical
Care Unit (CCU) in Egypt. This was a retrospective cohort study of HF patients discharged from
the CCU between January 2013 and December 2017. Guideline Adherence Index (GAI-3) was used
to assess guideline-directed prescribing at discharge. Multidisciplinary care was introduced to the
CCU on 1 January 2016. The study included 284 HF patients, mean (±SD) age 66.7 ± 11.5 years,
53.2% male. Heart failure with reduced ejection fraction affected 100 patients (35.2%). At discharge,
loop diuretics were prescribed to 85.2% of patients; mineralocorticoid receptor antagonists to 54.9%;
angiotensin-converting enzyme inhibitors/angiotensin receptor blockers to 51.4%; and β-blockers
to 29.9%. Population Guideline Adherence Index (GAI-3) was 45.5%. High-GAI was prescribed to
136 patients (47.9%). Patients with High-GAI were younger; less affected by chronic kidney disease and
had fewer comorbidities than those without High-GAI. Prescription of β-blocker increased (24.1% vs.
38.6%, p < 0.001) and digoxin utilization decreased (34.7% vs. 23.7%, p < 0.049) after the introduction
of the multidisciplinary care. The inclusion of a clinical pharmacist in the multidisciplinary care team
may have a role in optimizing the prescribing of HF guideline-directed therapies at discharge from
this setting.
Keywords: pharmacist; heart failure; multidisciplinary care; guideline adherence; guideline-directed
medical therapy; Egypt
1. Introduction
The prevalence of heart failure (HF) is estimated to be 2% of the total adult population in
developed countries, rising to greater than 10% among people aged 70 years and older [1]. In Europe,
HF exacerbation is the cause of more than 1 million hospitalizations annually [2] and rehospitalization
is common among patients with HF following their initial discharge [3]. European data demonstrate
that 12-month all-cause mortality rates for hospitalized and ambulatory HF patients are 17% and
7%, respectively [4]. The exact prevalence of HF in Egypt is unknown; however, evidence suggests
that the disease emerges a decade younger in the Middle East and North Africa (MENA) region than
in Europe [5,6]. The available MENA data suggest that HF patients are more likely to be severely
symptomatic due to delayed diagnosis or late presentation to healthcare settings in comparison
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to patients from Europe and North America [7,8]. While recent data for Egypt are not available,
the International Congestive Heart Failure registry showed that for HF patients, one-year all-cause
mortality in the Middle East was 9%, and in Africa was 34% [8].
In HF, the international clinical practice guidelines strongly recommend the prescription of HF
guideline-directed medical therapies (GDMT) at target doses [9–13]. Guideline-led prescribing is
associated with clinical benefits including improved survival rates; reduced frequency of hospitalization
and rehospitalization; reduced length of stay; reduction in adverse cardiovascular events; and decreased
use of mechanical ventilation [10,11,14]. In the BIOSTAT-CHF and QUALIFY studies, the optimization
of HF GDMT and the prescription of ≥50% of target doses of these agents demonstrated short- and
long-term benefits in patient survival and rehospitalization outcomes [14,15].
Patient hospitalization presents an opportunity to implement HF GDMT in a monitored setting.
However, studies show that discharge therapeutic plans for HF patients are often not adherent to the
clinical practice guidelines [16,17]. In one long-term registry, prescription rates of HF GDMT at hospital
discharge were 83.6% for diuretics, 77% for angiotensin-converting enzyme inhibitors/angiotensin
receptor blockers (ACEI/ARB), 71.8% for β-blockers, 55.3% for mineralocorticoid receptor blockers
(MRA), and 3.2% for ivabradine [17]. Two studies by Gilstrap and colleagues identified reasons for
the omission of HF GDMT during hospitalization or at discharge including renal dysfunction and
hypotension [18,19].
Many HF patients are first cared for in the critical care setting and the prescribing decisions made
in this setting may influence future prescribing and medical stability. In Egypt, many patients admitted
to the Critical Care Medicine Department affiliated to Cairo University, Faculty of Medicine, Qasr
Al-Ainy are discharged directly from critical care to their homes and decisions about long-term HF
medications are made at this timepoint. However, little is known about the quality of HF prescribing at
discharge from critical care settings. The acutely ill HF population represents a challenge for prescribers
as these patients are often older, suffering from multiple acute comorbidities, prescribed appropriate
and potentially inappropriate polypharmacy, and are more likely to experience contraindications to
therapies [3,17,20]. Therefore, discharge prescribing may not be optimized in this population [3,17].
Multidisciplinary care is considered the gold standard model for the seamless delivery of
guideline-directed HF management [11,21] and implementation of multidisciplinary care can improve
the transition of care and reduce rehospitalization rates by up to 30% [22,23]. The inclusion of clinical
pharmacists in HF multidisciplinary care teams has been shown to optimize guideline-led prescribing
during and after hospitalization [24]. However, there are no reports of multidisciplinary HF care
involving a clinical pharmacist in critical care settings.
This study aimed to assess the impact of the clinical pharmacist as a member of a multidisciplinary
team on the quality of prescribing to HF patients at discharge from a Critical Care Unit (CCU) in Egypt.
2. Materials and Methods
This is a retrospective cohort study of HF patients hospitalized in the 53-bed CCU of Cairo
University Hospitals between 1 January 2013 and 31 December 2017. Ethics approval was granted by
the Research and Ethics Committee of Future University in Egypt, Cairo, Egypt (registration number
REC-FPSPI-9/56). Permission to conduct the research using the electronic database of the department
was granted by the Management Board of the Critical Care Medicine Department of Cairo University
Hospitals prior to data collection. As this was a retrospective study and data were anonymized
at source, patient consent was not required for the study. The study is reported according to the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [25].
Patients were included if they were ≥18 years on the date of admission, had a diagnosis of
HF, had an electronic record of discharge medications, and were discharged from the CCU during
the study period. Patients were excluded from the study if they died during admission or if they
remained an inpatient on the final day of the study period. The diagnosis and type of HF were based
on data recorded in the patient’s electronic medical record. According to the European Society of
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Cardiology (ESC) guidelines that were in place during the study period, heart failure with reduced
ejection fraction (HFrEF) was defined as an ejection fraction ≤40% [10]. Data accessed in the patient’s
electronic medical record included age, gender, admission date, discharge date, presenting complaint,
comorbidities, laboratory investigations, and medical investigations. The following information on
discharge medications was also accessed in the electronic medical records: drug name, dose, and
frequency. Hyperpolypharmacy was defined as the prescription of ≥10 regular medications per day.
Hyperpolypharmacy was used as a measure of medication burden as this population is prescribed a
high number of medications, both for HF and for comorbidities [26]. The median dose of loop diuretic
was calculated to reflect HF severity [27].
The ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
were used in this study as they are the guidelines that were in place for most of the study timeframe [10].
The primary outcome of the study was to assess HF guideline-led prescribing at discharge using
the Guideline Adherence Index (GAI-3) [28], the adjusted GAI-3 [29], and the GAI-based target
dose [30]. The GAI-3 was calculated as the ratio of the medications prescribed to the medications
that should theoretically have been prescribed according to the guidelines. These medications are
agents within the following classes: ACEI/ARB, evidence-based β-blockers (EBBB) and MRA [10,28].
The EBBBs in HF are bisoprolol, carvedilol, metoprolol succinate, and nebivolol [10]. The adjusted
GAI-3 considered the patient’s contraindications to these therapies as outlined in the guidelines
(Table 1) [10,29,31]. The GAI-based target dose was calculated as a prescription of ≥50% of the
guideline-recommended target dose of each of the three GAI medications (Table 1) [10,30]. The study
population was then subdivided into those with High-GAI management; that is the prescription of ≥2
of the GAI-3 medications and those with Low-GAI management; that is the prescription of ≤1 GAI-3
medication [31].
Multidisciplinary care was provided to all patients in the CCU from 1 January 2016 onwards.
The multidisciplinary care team consisted of critical care physicians and clinical pharmacists. The clinical
pharmacy team consisted of (i) a clinical pharmacy supervisor with 15 years’ experience as a critical
care pharmacist in the CCU, who held a Master of Science and a Doctor of Philosophy degree in
Clinical Pharmacy from Cairo University; (ii) a pharmacist who held a PharmD from the Faculty of
Pharmacy, Cairo University—this is a two-year post-graduate program after a five-year bachelor of
Pharmaceutical Sciences or Bachelor of Clinical Pharmacy degree; and (iii) four pharmacists who held
a Bachelor of Clinical Pharmacy degree from the Faculty of Pharmacy, Cairo University. The clinical
pharmacists were available daily at the CCU from 8 am to 3 pm except on Fridays. The role of the
clinical pharmacist was (i) to participate in the daily morning physician-led ward round to provide
prescribing recommendations; (ii) to perform medication review and medication reconciliation on
admission in order to identify drug therapy problems; and (iii) to provide a drug information service
to the critical care physicians.
Normally distributed data were presented as mean ± standard deviation (SD), and non-normal
data as the median and the interquartile range. Categorical data were presented as frequencies and
percentages. Comparisons between (i) patients with High-GAI and Low-GAI based management and
(ii) patients receiving care before and after the introduction of multidisciplinary care were conducted
using independent Student’s t-test or Mann–Whitney U test for continuous data and Chi-square or
Fisher’s exact test for categorical data. All tests were two-tailed, and a p-value < 0.05 was regarded as
statistically significant.
Univariable logistic regression analysis was performed, and a multivariable logistic regression
model was developed in order to determine the clinical factors associated with High-GAI achievement.
The multivariable logistic regression model included the variables that were considered clinically
relevant and variables that demonstrated a significant difference in the comparison between High-GAI
and Low-GAI populations. The adjusted odds ratios (OR) and 95% confidence intervals (CI) of the
multivariable analysis were reported. Data were analyzed using SPSS® (IBM SPSS Statistics for
Windows, Version 22.0., IBM Corp., Armonk, NY, USA).
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Table 1. Guideline-directed medical therapies, their contraindications, and target doses as described in
the European Society of Cardiology Guidelines for the Diagnosis and Treatment of Acute and Chronic
Heart Failure 2012 [10].
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Agents listed are those agents from each class, prescribed to one or more patients in the study population. ACE,
angiotensin-converting enzyme.
3. Results
3.1. Baseline Profile and Characteristics of Heart Failure Patients
Data were available for 284 patients who had a documented diagnosis of HF. The mean ± SD
age of the patients was 66.7 ± 11.5 years, and 53.2% were male. Ejection fraction was available for
220 patients, and the mean ± SD ejection fraction was 45.1% ± 16.7%. HFrEF affected 100 patients
(35.2%). Coronary artery disease was the HF etiology in 132 patients (46.5%), and acute coronary
syndrome was the main presenting complaint in 81 patients (28.5%). The mean ± SD number of
comorbidities was 5.2 ± 2.4; with hypertension (n = 140, 49.3%), diabetes (n = 130, 45.8%) and atrial
fibrillation (n = 109, 38.4%) the most frequently occurring comorbidities (Table 2).
Table 2. Baseline characteristics and medications profile of the total population, patients prescribed
High-GAI, and patients prescribed Low-GAI, N = 284 patients.
N = 284 Patients
Total Population High-GAI Low-GAI p-Value
(N = 284) (N = 136) (N = 148)
Clinical profile
Age (years) 66.7 ± 11.5 62.6 ± 10.7 70.5 ± 11.0 <0.001
Male 151 (53.2) 89 (65.4) 62 (41.9) <0.001
Mean arterial pressure (mmHg) 94.9 ± 17.6 93.3 ± 19 96.3 ± 16.2 0.436
Heart rate (bpm) 86.2 ± 22.0 87.9 ± 21.6 84.6 ± 22.3 0.701
HFrEF 100 (35.2) 67 (49.3) 33 (22.3) <0.001
Hypertension 140 (49.3) 69 (50.7) 71 (48.0) 0.313
Atrial fibrillation 109 (38.4) 48 (35.3) 61 (41.2) 0.541
Coronary artery disease 132 (46.5) 69 (50.7) 63 (42.6) 0.376
Diabetes 130 (45.8) 60 (44.1) 70 (47.3) 0.132
Chronic kidney disease 80 (28.2) 30 (22.1) 50 (33.8) 0.028
Asthma/COPD 64 (22.5) 34 (25.0) 30 (20.3) 0.812
Number of comorbidities 5.2 ± 2.4 4.9 ± 2.3 5.6 ± 2.5 0.017
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Table 2. Cont.
N = 284 Patients
Total Population High-GAI Low-GAI p-Value
(N = 284) (N = 136) (N = 148)
Clinical Status at Discharge
Low blood pressure (<90/60 mmHg) 9 (3.5) 8 (6.7) 1 (0.7) 0.011
High blood pressure (>140/90 mmHg) 88 (34.6) 34 (28.6) 54 (40.0) 0.214
Heart rate ≤ 70 bpm 107 (37.7) 46 (33.8) 61 (41.2) 0.333
Heart rate ≥ 100 bpm 57 (20.1) 28 (25.5) 29 (24.0) 0.412
Hyperkalemia (K+ > 5.0 mg/dL) 9 (3.2) 3 (2.2) 6 (4.1) 0.877
High blood urea nitrogen (>20 mg/dL) 153 (53.9) 63 (46.3) 90 (60.8) <0.01
High serum creatinine (>2.5 mg/dL) 31 (10.9) 7 (5.1) 24 (16.2) <0.01
Length of stay 9.8 ± 6.9 9.3 ± 7.4 10.3 ± 6.5 0.049
Discharge Medications Profile
ACEI/ARB 146 (51.4) 125 (91.9) 21 (14.2) 0.011
EBBB 85 (29.9%) 67 (49.3) 18 (12.2%) 0.214
MRA 156 (54.9) 122 (89.7) 34 (23.0) 0.333
Digoxin 86 (30.3) 48 (35.3) 38 (25.7) 0.412
Loop Diuretics 242 (85.2) 120 (88.2) 122 (82.4) 0.877
Ivabradine 31 (10.9) 21 (15.2) 10 (6.8) <0.01
Regular medications 9.1 ± 2.5 9.3 ± 2.3 8.9 ± 2.6 0.049
Hyperpolypharmacy 121 (43.7) 59 (43.4) 62 (41.9) 0.011
Device-based therapy * 38 (13.4) 19 (14.0) 19 (12.8) 0.214
Major Prescribing Patterns at Discharge
Loop diuretic as monotherapy 45 (15.8) - 45 (30.4) -
ACEI/ARB + β-blocker 56 (19.7) 56 (41.7) - -
ACEI/ARB + MRA 110 (38.7) 110 (80.9) - -
Loop diuretic + ACEI/ARB 123 (43.3) 108 (79.4) 15 (10.1) <0.01
Loop diuretic + MRA 146 (51.4) 114 (83.8) 32 (21.6) <0.01
Loop diuretic + MRA + Digoxin 54 (19.1) 43 (31.6) 11 (7.4) 0.021
Loop diuretic + ACEI/ARB + MRA 102 (35.9) 102 (75.0) - -
Comparisons were made between Heart Failure patients with High-GAI and Low-GAI. Categorical variables are
expressed as frequencies and percentages. Continuous variables are expressed as mean ± standard deviation;
* Device-based therapy: implantable cardiac defibrillator, cardiac resynchronization therapy, or left ventricular
assistance device; ACEI/ARB, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker; COPD,
chronic obstructive pulmonary disease; EBBB, evidence-based β-blocker; GAI, Guideline Adherence Index; HFrEF,
heart failure with reduced ejection fraction; K+, serum potassium; MAP, mean arterial blood pressure; MRA,
mineralocorticoid receptor antagonist.
3.2. Prescribing to the Heart Failure Population
At discharge, the mean ± SD number of daily medications was 9.1 ± 2.5 (Table 2). Fourteen
patients (4.9%) were not prescribed any HF medications. Prescription rates for the three GDMT were
ACEI/ARB, n = 146 (51.4%); EBBB, n = 85 (29.9%); and MRA, n = 156 (54.9%). A combination of two
GDMT was prescribed to 94 (33.1%) patients, and all three medicines were prescribed to 42 (14.8%)
patients. Prescription of ≥50% of the guideline-recommended target doses of ACEI/ARB, EBBB, and
MRA was achieved in 40 (14.1%), 21 (7.4%) and 145 (51.5%) patients, respectively. Although not a
GAI-3 medication, the most frequently prescribed HF medication was loop diuretics (n = 242, 85.2%),
with 45 patients (15.8%) prescribed a loop diuretic as their only HF medication and 43 (15.2%) patients
prescribed two or more loop diuretic agents at discharge.
No patient experienced a contraindication to ACEI/ARB or MRA. At least one contraindication to
EBBB therapy was present in 70 (24.6%) patients, 23 (8.1%) having a second or third-degree AV-block,
and 47 (16.5%) having asthma. Of these 70 patients, 21 (30.0%) were prescribed an EBBB at discharge.
Population mean GAI-3 was 45.5%, and adjusted GAI-3 was 51.3%. The GAI-3 target dose
was 24.3%.
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3.3. High-GAI and Low-GAI Achievement
High-GAI based management was achieved in 136 patients (47.9%). These High-GAI patients
were younger (62.6 ± 10.7 vs. 70.5 ± 11.0 years, p < 0.001); more likely to be male (65.4% vs. 41.9%,
p < 0.001); more likely to have HFrEF (49.3% vs. 22.3%, p < 0.001); had fewer comorbidities (4.9 ± 2.3
vs. 5.6 ± 2.5, p = 0.017); and were less likely to have chronic kidney disease (22.1% vs. 33.8%, p = 0.028)
than those patients with Low-GAI. The prescription of recommended target doses of ACEI/ARB, EBBB,
and MRA was significantly higher in the High-GAI cohort than the Low-GAI cohort (Figure 1). Higher
median doses of loop diuretics were prescribed to the Low-GAI cohort in comparison to the median
doses prescribed to the HF patients with a High-GAI based management; however, the difference did
not reach significance, 40 mg/day [60–120 mg/day] vs. 20 mg/day [40–80 mg/day], p = 0.731.
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3.4. Contribution of Multidisciplinary Care
There were few differences in demographics or comorbidities between HF patients receiving
the routine care of the critical care physician (n = 170) and those receiving multidisciplinary care
(n = 114) (Supplementary Table S1). The rate of atrial fibrillation was higher among those in the
multidisciplinary care arm and patients in the multidisciplinary care arm were more likely to achieve a
heart rate <70 bpm and to have elevated blood urea nitrogen. There as no difference in the edian
dose of loop diuretics between the two groups. Medications prescribed to the two cohorts are described
in Table 3. Patients who received multidisciplinary care were more likely to be prescribed an EBBB
(38.6% vs. 24.1 , p < 0.001) and were less likely to be prescribed digoxin (23.7% vs. 34.7%, p = 0.049)
than those receiving physician-only c re.
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Table 3. Prescribing at discharge for patients receiving routine care and patients receiving
multidisciplinary care, N = 284 patients.







ACEI/ARB 91 (53.5) 55 (48.2) 0.345
ACEI/ARB ≥ 50% Target dose 25 (14.7) 15 (13.2) 0.456
EBBB 41 (24.1) 44 (38.6) <0.001
EBBB ≥ 50% Target dose 9 (5.3) 12 (10.5) 0.218
MRA 99 (58.2) 57 (50.0) 0.546
MRA ≥ 50% Target dose 93 (54.7) 52 (45.6) 0.617
Digoxin 59 (34.7) 27 (23.7) 0.049
Loop diuretic 149 (87.6) 93 (81.6) 0.341
Dual loop diuretics 19 (11.2) 23 (20.2) 0.032
Ivabradine 18 (10.6) 13 (11.4) 0.421
Regular medications 9.0 ± 2.4 9.3 ± 2.6 0.784
Hyperpolypharmacy 71 (41.8) 50 (43.9) 0.435
Discharge Guideline Adherence Indices
GAI-3 (%) 45.2 45.7 0.598
Adjusted GAI-3 (%) 50.0 52.6 0.854
GAI-Target dose (%) 25.0 23.0 0.349
High-GAI 81 (47.6) 55 (48.2) 0.881
Comparisons were made between heart failure care provided before and after the implementation of a clinical
pharmacy service at the critical care unit. Categorical variables are expressed as frequencies and percentages.
Continuous variables are expressed as mean ± standard deviation. § Routine care refers to the medical care provided
by the critical care physician only while multidisciplinary care refers to the medical care provided by the critical care
physician and clinical pharmacist; ACEI/ARB, angiotensin-converting enzyme inhibitor or angiotensin receptor
blocker; CCB, calcium channel blocker; EBBB, evidence-based β-blocker; GAI, guideline adherence index; MRA,
mineralocorticoid receptor antagonist.
3.5. Logistic Regression Analysis
The multivariable model included the following variables: age, sex, the number of comorbidities,
HFrEF, blood urea nitrogen >20 mg/dL, serum creatinine >2.5 mg/dL, and prescription of ivabradine.
In the multivariable logistic regression analysis, the clinical factors associated with High-GAI
management were age (adjusted OR 0.93, 95% CI 0.90–0.96), serum creatinine >2.5 mg/dL (adjusted
OR 0.55, 95% CI 0.37–0.82) and HFrEF (adjusted OR 1.16, 95% CI 1.05–1.25). The model estimation
correctness was 78.8% and Nagelkerke’s R2 = 0.44.
4. Discussion
The present study is the first assessment of HF guideline-led prescribing at discharge from a
critical care setting. At discharge, the mean guideline adherence was 45.5%, adjusted GAI-3 was 51.3%,
and when adjusted for the achievement of ≥50% target dose, it was 24.3%. After the implementation
of multidisciplinary care involving a pharmacist, the adherence level did not significantly change,
however, some changes in the prescribing patterns of individual HF medications were observed in
particular an increase in the prescription of EBBB.
The prescription rates and the level of High-GAI achievement reported in this study are lower
than those reported in QUALIFY. QUALIFY is an international registry that included Egyptian HF
patients recently discharged primarily from cardiology settings rather than CCU settings. [32] A recent
systematic review found that in studies published from 2005 to 2016, GAI-3 ranged from 14% to 95%,
with a mean GAI-3 of 62.9% [31]. While the GAI-3 reported here is lower than this international
mean [31], it is comparable to recently reported GAI-3 in Brazil (41%) [33] and Korea (43%) [34],
however, these studies were conducted in different settings. The study population here is more acutely
ill than others reported in the GAI literature and this represents a serious challenge to prescribers
in comparison to ambulatory HF populations or HF populations hospitalized in non-critical care
settings [31].
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The differences reported here between patients with High-GAI and those with Low-GAI reflect
the adverse impact of age and multimorbidity on guideline adherence. Patients with Low-GAI were
older, had a higher comorbidity burden and higher serum creatinine levels than High-GAI patients.
The adjusted GAI-3 considers the contraindications to therapy listed in the guidelines. However,
in the present study, adjusting for these contraindications had little effect on correcting guideline
adherence levels. Meanwhile, it is possible that prescribers take other considerations into account when
prescribing GDMT. For instance, almost 30% of the population experienced chronic kidney disease,
and these patients were significantly less likely to be prescribed High-GAI than patients with normal
kidney function. This suggests that reduced renal function may represent a barrier to the appropriate
prescription of ACEI/ARB and MRA in acute-care settings [15,35].
In the present study, the high prescription rate of loop diuretics and MRAs reflects the acutely ill
status of the patients admitted to the critical care setting. Given that the medications were recorded
at discharge this high rate of diuretic use may also indicate prescribers’ preference for short-term
symptom relief over longer-term disease-modifying interventions. Additionally, the high rate of
loop diuretics prescribed and low rate of EBBB may suggest that these patients remain congested.
The prescription of a fixed-dose formulation containing furosemide and spironolactone contributed to
higher target dose achievement among patients prescribed MRA than the other GDMT. This fixed-dose
combination is available on the Egyptian market at a low price. These affordable products may
enhance patient compliance and persistence, and prescribers may be influenced by such practical
considerations. Furthermore, a high incidence of diuretic resistance has been reported among Egyptian
patients, and adjunct medications such as thiazide diuretic metolazone are not commonly included in
the hospital formularies [6,36]. The inaccessibility of adjunct diuretics such as metolazone may also
have contributed to the unexpectedly high rate of prescription of two or more loop diuretics.
The low rate of target dose achievement reported here may reflect the critical care setting from
which the patients are being discharged, the prescribers’ focus on acute illness rather than long-term
outcomes and an assumption that doses may be titrated upwards in an ambulatory cardiology setting.
For instance, 53% of patients in the “BIOSTAT-CHF” study required a 12-week stepwise approach to
reach ≥50% of the recommended target dose [15]. This highlights the need for introducing patient
education and counseling sessions for HF patients at discharge. Such a service would advise patients
of the importance of follow-up, the need for medication optimization over the coming months, and the
importance of medication adherence.
There is no doubt that HF management is complex and multifaceted. As a consequence, guidelines
recommend a multidisciplinary approach to the optimal and seamless delivery of HF care [3,11].
Egyptian reports before 2015 show high rates of digoxin use and underutilization of EBBB [6,37]. In the
present study, the implementation of multidisciplinary care significantly increased EBBB prescription
and significantly decreased digoxin prescription. The prescribing changes reported here indicate
improved adherence to the most recent ESC guidelines [11]. However, the overall GAI-3 and the
proportion of patients achieving High-GAI-based management did not significantly increase with
the implementation of multidisciplinary care. The pharmacists in the multidisciplinary team could
make a recommendation about patient medications but had no authority to implement the changes
to inpatient or discharge prescriptions. Unfortunately, the acceptance rate of interventions was
not available in this study. Others have reported on the phenomenon of physicians’ encroachment
and their reluctance to alter a colleague’s prescription despite appropriate recommendations made
by clinical pharmacists [38–40]. This may adversely affect the influence on prescribing quality of
multidisciplinary care.
Some limitations of this study must be acknowledged. The study is retrospective, single-centered,
and includes only the patients’ discharge medications, therefore medications trialed on an inpatient
basis could not be assessed. As it was not possible to randomize and in order to reduce the risk of
selection bias, all HF patients discharged before the introduction of the service were compared to all
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HF patients discharged after the introduction of the multidisciplinary HF service. Unfortunately, with
this retrospective design, a causal relationship could not be assessed.
5. Conclusions
This study is the first to consider HF guideline adherence on discharge from a critical care unit and
the impact of multidisciplinary care in Egypt, or indeed, any low-middle income country. It identifies
some inconsistencies between guideline-recommended HF prescribing and the current routine practice
and also highlights the potential for greater pharmacist involvement in the HF multidisciplinary team.
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